HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
Expanding HanchorBio’s data-enabled approach from molecule design to portfolio and market insight
[Taipei, Shanghai, San Francisco | April 24, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, today announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.
Through access to Bloomberg’s data and research content, including Bloomberg Intelligence’s Disease dashboard via the Bloomberg Terminal, HanchorBio gains valuable insights into science, strategy and markets, supporting its understanding of biopharma innovation, competitive landscapes, partnerships, and global biotech trends across public and private companies.
For HanchorBio, the use of intelligence in drug development did not begin with market analysis. It began in molecule design.
In developing HCB101, HanchorBio applied AI-guided structural engineering, using AlphaFold-informed analyses, to inform the design of its SIRPα–IgG4 Fc fusion protein. The program combined structure-informed design with a 178-million-variant SIRPα phage-display library and iterative screening to eliminate variants that bind normal cells, enrich high-affinity tumor CD47 binders, and identify rare clones with minimal red blood cell binding. That early experience contributed to a broader company view: intelligence and decision science should extend beyond discovery, development, medical and regulatory strategy, business development, and portfolio management.
“From the beginning, we have believed that biotechnology innovation requires both scientific originality and the ability to make better decisions as complexity increases,” said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio. “Our early work on HCB101 reflected that mindset in scientific design. We see the next step as extending that philosophy beyond molecule engineering into how we develop programs, prioritize opportunities, and build HanchorBio for long-term global growth.”
HanchorBio views the use of Bloomberg data and research content as part of a broader effort to support decision-making across the drug development lifecycle—from scientific design and clinical development to regulatory execution, external portfolio, and market strategy.
“Scientific innovation alone is not enough,” added Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and CEO (USA) of HanchorBio. “Clinical development, medical science, regulatory affairs, and strategic execution are increasingly interconnected. Our goal is to apply stronger intelligence and decision-making discipline across the full drug development lifecycle so that better analysis can translate into better decisions, stronger execution, and ultimately better outcomes for patients.”
“In a fast-moving global biopharma environment, high-quality competitive and market intelligence is increasingly important for partnership strategy, portfolio positioning, and capital markets engagement,” commented Yuehua Cong, PhD, Chief Business Officer of HanchorBio. “Access to Bloomberg’s data and research content adds a valuable perspective by helping us monitor pipeline activity, licensing trends, investor dynamics, and broader industry developments.”
By combining scientific, development, and strategic insight, HanchorBio aims to strengthen its ability to identify opportunities, evaluate risk, and advance differentiated therapies in the global biopharmaceutical landscape.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.
漢康生技與彭博合作 強化藥物開發及全球生物製藥戰略情報能力
從分子設計到產品組合與市場洞察，持續深化漢康生技的數據驅動決策體系
漢康生技，一家致力於開發腫瘤免疫及自體免疫相關疾病次世代免疫療法的全球臨床階段生物技術公司，今日宣佈與彭博合作，進一步強化公司在產品組合規劃、產品線開發、競爭監測、業務拓展及資本市場活動等面向的戰略決策能力。
透過運用彭博的數據與研究內容，包括經由彭博終端取得的彭博行業研究疾病中心儀表板，漢康生技得以獲取更全面的科學、產業及市場洞察，進一步掌握生物製藥創新趨勢、競爭格局、合作機會，以及全球生物技術產業的發展動態。
對漢康生技而言，將情報分析導入藥物開發的實踐，並非始於市場分析，而是始於分子設計。
在開發HCB101的過程中，漢康生技運用AI引導的結構工程方法，並借助AlphaFold輔助分析，作為其SIRPα–IgG4 Fc融合蛋白設計的基礎。該計畫結合結構導向設計、涵蓋1.78億個SIRPα變體的噬菌體展示庫，以及反覆運算篩選策略，逐步剔除與正常細胞結合的變體，篩選出僅對腫瘤細胞CD47展現高親和力、與紅血球結合極低的候選藥物。這一早期研發經驗，也進一步促成公司對做出具有更高價值的科學決策有了全面的體認：從新藥發現、臨床開發，到醫學與註冊策略、業務拓展及產品組合管理，均需建立在更具系統化的資訊整合與判斷基礎之上。
「從創立之初，我們就深信，生物技術創新不僅需要科學上的原創性，也需要在高度複雜的環境中持續做出更好決策的能力，」漢康生技創辦人、董事長兼執行長劉世高博士表示，「我們在HCB101早期研發上的工作，正體現了這項理念如何落實於科學設計。接下來，我們希望將這樣的思維，應用在從分子工程進一步延伸至計畫開發、機會優先排序，以及企業長期成長能力的建構之中。」
漢康生技表示，運用彭博的數據與研究內容，是公司持續強化藥物開發全生命週期決策能力的一環，涵蓋科學設計、臨床開發、註冊執行、外部產品組合評估及市場策略等關鍵面向。
「僅有科學創新並不足夠，」漢康生技集團總裁兼醫療長、美國子公司執行長陸英明博士表示，「臨床開發、醫學科學、註冊事務與戰略執行之間的連動性正日益提高。我們的目標，是在整個藥物開發生命週期中建立更強的情報整合與決策紀律，讓更深入的分析轉化為更好的判斷、更強的執行力，並最終為患者帶來更佳的治療結果。」
「在快速變動的全球生物製藥環境中，高品質的競爭與市場情報，對合作策略、產品組合定位及資本市場溝通的重要性日益提升，」漢康生技商發長叢越華博士表示。「透過彭博的數據與研究內容，我們得以更有效掌握產品線動態、授權趨勢、投資人動向及整體產業發展，為公司提供重要的決策視角。」
透過整合科學、開發與戰略層面的洞察，漢康生技將持續提升其在全球生物製藥格局中辨識機會、評估風險及推進差異化療法的能力。
關於漢康生技
漢康生技（股票代碼：7827.TPEx）是一家全球臨床階段的生物技術公司，專注於腫瘤免疫學及自體免疫疾病領域，研發總部設於台北，並在上海及美國舊金山灣區設有運營辦公室。公司由一支在生物藥發現與全球開發方面擁有豐富成功經驗的資深團隊領導，致力於重塑癌症治療格局。漢康生技專有的Fc基礎設計生物藥平台能夠開發具有多種靶向模式的多功能生物藥，旨在激活先天性與適應性免疫通路，以突破當前抗PD-1/L1免疫療法的局限。該平台已在多個體內腫瘤動物模型中成功獲得概念驗證數據。通過差異化的分子研發策略與可規模化的CMC工藝開發，漢康生技正推進一系列創新生物藥產品線，致力於解決尚未被滿足的重大醫療需求。